Structure via PubChem · Public domain (PubChem)
cenobamate
Sign in to saveCenobamate, sold under the brand names Xcopri (US) and Ontozry (EU), is a medication used for the treatment of partial-onset seizures, a kind of epilepsy, in adults. It is taken by mouth.
Chemical data
- Formula
- C10H10ClN5O2
- Molecular weight
- 267.67 g/mol
- IUPAC name
- [(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] carbamate
- SMILES
- C1=CC=C(C(=C1)[C@H](CN2N=CN=N2)OC(=O)N)Cl
- InChIKey
- GFHAXPJGXSQLPT-VIFPVBQESA-N
- XLogP
- 1.5
- Polar surface area
- 95.9 Ų
- H-bond donors
- 1
- H-bond acceptors
- 5
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 2020
- Admin. routes
- oral
- Indications
- epilepsy, partial epilepsy, Seizure, liver disease
via ChEMBL · EBI
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 267.052
Show 4 more facts
- canonical SMILES
- C1=CC=C(C(=C1)C(CN2N=CN=N2)OC(=O)N)Cl
- chemical formula
- C₁₀H₁₀ClN₅O₂
- isomeric SMILES
- C1=CC=C(C(=C1)[C@H](CN2N=CN=N2)OC(=O)N)Cl
- subject has role
- active ingredient
via Wikidata · CC0
~5 min read
Encyclopedic overview
12 sectionsContents
- Medical uses
- Contraindications
- Adverse effects
- Overdose
- Interactions
- Pharmacology
- Mechanism of action
- Pharmacokinetics
- History
- Society and culture
- Legal status
- References
Cenobamate, sold under the brand names Xcopri (US) and Ontozry (EU), is a medication used for the treatment of partial-onset seizures, a kind of epilepsy, in adults. It is taken by mouth.
Cenobamate was approved for medical use in the United States in November 2019, and placed in Schedule V of the Controlled Substances Act in March 2020. Cenobamate was authorized for medical use in the European Union in March 2021, approved for use in the UK in December 2021, and approved for use in Canada in June 2023.
Excerpted from Wikipedia’s “cenobamate” article, available under the CC BY-SA 4.0 licence.